Horizon Therapeutics

But I can give you an example of how you would value that in that when we did, uh, Raptor and Precizby, we were probably halfway into the market penetration with, uh, with Precizby.

Uh, sales was at about a hundred and thirty million a year, and Raptor was acquired for eight hundred million by Horizon Therapeutics.

So the multiples off revenues are, are significant and, and it gives a good comp for us.

Well, I know we're gonna get back to the investment thesis and the comp later, but I just thought it'd be in- uh, important to show that the profile of a twice approved drug with a new formulation is significantly different than an absolutely new molecule, new, a new mechanism that's unproven and, and quite binary.